Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ENOXAPARIN

All injection strengths: general benefit

Other products in the same Health Canada class (B01A, B01AB) — coverage varies; not interchangeable

  • Dalteparin (Fragmin): limited Use 186, 187, 188, 189
  • Nadroparin (Fraxiparine): limited Use 186, 187, 188, 189
  • Tinzaparin (Innohep): limited Use 186, 187, 188, 189, 323
  • Apixaban (Eliquis): general benefit
  • Dabigatran etexilate (Pradaxa): general benefit, Not a benefit
  • Edoxaban (Lixiana): general benefit

5 more in the class list below

Noromby · DIN 02506459 · 30mg/0.3mL · injection, 0.3 mL pre-filled syringe (preservative-free)

General benefitMarketed · checked 2026-09-20
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Noromby · DIN 02506459 Manufacturer: Juno Pharmaceuticals Corp.; listing date 2021-06-30 Health Canada: Marketed since 2026-05-28 · brand NOROMBY · ATC B01AB05 ENOXAPARIN · form Solution · route Intravenous, Subcutaneous · ingredients ENOXAPARIN SODIUM 30 MG/0.3ML · company Juno pharma canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Noromby: Formulary list price $4.9124/unit (unit not stated in source; not the patient's cost)

Ministry pays: $4.9124 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99582 · Verify on the e-Formulary ↗ (DIN 02506459)

Source record
DIN 02506459: Noromby Raw flags: sec3=Y Item: 201200122; group id 254; item number 0461; lccId None; manufacturer id JUN Source form: Inj Sol-0.3mL Pref Syr (Preservative-Free); strength: 30mg/0.3mL Recorded listing: General benefit Source prices (unrounded): $4.9124; ministry $4.9124 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02506459 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99582
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (20:12 Coagulants and Anti-Coagulants) and how they are covered

Matched class: 20:12 Coagulants and Anti-Coagulants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: APIXABAN, RIVAROXABAN Some products covered without a code (check the product listing): DABIGATRAN ETEXILATE, EDOXABAN, WARFARIN 20:12 Coagulants and Anti-Coagulants

DALTEPARIN SODIUM

· 10 products · Limited Use, codes 186, 187, 188, 189 · strengths: 3500IU/0.28mL, 7500IU/0.3mL, 2500IU/0.2mL, 5000IU/0.2mL, 10000IU/0.4mL, 12500IU/0.5mL, 15000IU/0.6mL, 18000IU/0.72mL, 16500IU/0.66mL, 25000IU/mL · Inj Pref Syr, Inj Pref Syr-0.66mL Pk, Multidose 3.8mL Pk

NADROPARIN CALCIUM

· 7 products · Limited Use, codes 186, 187, 188, 189 · strengths: 9500IU/mL, 19000IU/mL · Pref Syr-0.3mL Pk, Pref Syr-0.4mL Pk, Pref Syr-0.6mL Pk, Pref Syr-0.8mL Pk, Pref Syr-1.0mL Pk

TINZAPARIN SODIUM

· 11 products · Limited Use, codes 186, 187, 188, 189, 323 · strengths: 2500IU/0.25mL, 8000IU/0.4mL, 12000IU/0.6mL, 16000IU/0.8mL, 3500IU/0.35mL, 4500IU/0.45mL, 10000IU/0.5mL, 14000IU/0.7mL, 18000IU/0.9mL, 10000IU/mL, 20000IU/mL · Inj Pref Syr, Inj-2mL Pk

APIXABAN

· 38 products · General benefit · strengths: 2.5mg, 5mg · Tab

DABIGATRAN ETEXILATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (4) · strengths: 75mg, 110mg, 150mg · Cap

RIVAROXABAN

· 48 products · General benefit · strengths: 2.5mg, 10mg, 15mg, 20mg · Tab

WARFARIN

· 23 products · Listed, not a benefit (8), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (1) · strengths: 1mg, 2mg, 2.5mg, 3mg, 4mg, 5mg, 6mg, 10mg · Tab

FONDAPARINUX SODIUM

· 4 products · Limited Use, codes 378 (2), Off-Formulary Interchangeable, not an ODB benefit (2) · strengths: 2.5mg/0.5mL, 7.5mg/0.6mL · Inj Sol-Pref Syr 0.5mL Pk (Preservative Free), Inj Sol-Pref Syr 0.6mL Pk (Preservative Free)

TICAGRELOR

· 10 products · Off-Formulary Interchangeable, not an ODB benefit (5), Limited Use, codes 441 (5) · strengths: 60mg, 90mg · Tab

EPTIFIBATIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.75mg/mL, 2mg/mL · 100mL Vial Pk, 10mL Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12 20:12:04 Direct Factor Xa Inhibitors

EDOXABAN

· 11 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (3), General benefit (8) · strengths: 15mg, 30mg, 60mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:04 20:12:16 Hemostatics

TRANEXAMIC ACID

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 500mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 20:12:16
Full class listing Related classes: 20:04 Antianemia Drugs, 20:16 Hematopoietic Agents, 20:24 Hemorrheologic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Indications have been granted on the basis of similarity between NOROMBY and NOROMBY HP and the reference biologic drug LOVENOX and LOVENOX HP. NOROMBY (enoxaparin sodium) is indicated for: • The prophylaxis of thromboembolic disorders (deep vein thrombosis) in patients undergoing: o orthopedic surgery of the hip or knee. In addition, NOROMBY is indicated in hospital or after hospital discharge for long-term prevention of venous thromboembolic diseases following hip replacement surgery. o high risk abdominal, gynecological, or urological surgeries; o colorectal surgery. • The prophylaxis of deep vein thrombosis (DVT) in medical patients who are at moderate risk of DVT and who are bedridden due to moderate to severe acute cardiac insufficiency (NYHA Class III or IV heart failure), acute respiratory failure revealing or complicating chronic respiratory insufficiency not requiring ventilatory support and acute respiratory infections (excluding septic shock), who require short-term prophylaxis of deep vein thrombosis. • The prevention of thrombus formation in the extra-corporeal circulation during hemodialysis. NOROMBY is also … https://pdf.hres.ca/dpd_pm/00084890.PDF PM date: 2026-05-28 Source product: NOROMBY; DIN 02506459; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.